-
公开(公告)号：US20170081415A1
公开(公告)日：2017-03-23
申请号：US15279853
申请日：2016-09-29
Applicant: Five Prime Therapeutics, Inc.
Inventor： Justin Wong , Maximiliano Vasquez
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/63
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
-
102.发明授权Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R) 有权编码结合集落刺激因子1受体（CSF1R）的抗体的核酸公开(公告)号：US09200075B2
公开(公告)日：2015-12-01
申请号：US14266209
申请日：2014-04-30
Applicant: Five Prime Therapeutics, Inc.
Inventor： Justin Wong , Maximiliano Vasquez
CPC classification number: C07K16/2866 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/63
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
Abstract translation: 提供了结合CSF1R的抗体。 还提供能够形成结合CSF1R的抗体的抗体重链和轻链。 提供编码CSF1R抗体的多核苷酸。 还提供了编码抗体重链和灯链的多核苷酸。 提供使用抗CSF1R抗体的方法。 这些方法包括但不限于治疗类风湿性关节炎，骨丢失和多发性硬化症的方法。
-
公开(公告)号：US09192683B2
公开(公告)日：2015-11-24
申请号：US14048841
申请日：2013-10-08
Applicant: Five Prime Therapeutics, Inc.
Inventor： Lewis T. Williams , Elizabeth Bosch , Stephen K. Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC: A61K39/00 , A61K38/18 , C07K14/475 , C07K14/50 , A61K47/48 , C07K14/71 , C07K14/765 , C07K16/28 , C07K17/08 , A61K45/06
CPC classification number: C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
Abstract translation: 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US20140341900A1
公开(公告)日：2014-11-20
申请号：US14357336
申请日：2012-11-13
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Thomas Harding , Servando Palencia , Li Long , Kevin Hestir
CPC classification number: A61K38/179 , A61K39/395 , A61K45/00 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6813 , C12Q1/686 , G01N33/5005 , A61K2300/00
Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
Abstract translation: 提供了治疗包含FGFR1基因扩增的癌症的方法。 在一些实施方案中，所述方法包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子。 在一些实施方案中，所述方法包括与至少一种另外的治疗剂组合施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子。
-
公开(公告)号：US20140274898A1
公开(公告)日：2014-09-18
申请号：US14185086
申请日：2014-02-20
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Thomas Brennan , Robert Dean , W. Michael Kavanaugh , Janine Powers
IPC: C07K14/71 , A61K31/506 , A61K31/473 , A61K38/17
CPC classification number: C07K14/71 , A61K8/64 , A61K31/473 , A61K31/506 , A61K38/179 , A61Q7/00
Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
Abstract translation: 促进毛发生长的方法本发明涉及一种促进毛发生长的方法，包括以足以促进毛发生长的量施用包含天然FGFR3 ECDs，变体，片段和融合分子的成纤维细胞生长因子受体3（FGFR3）细胞外结构域（ECD） 头发生长。
-
Patent Agency Ranking
公开(公告)号：US20140086840A1
公开(公告)日：2014-03-27
申请号：US14019684
申请日：2013-09-06
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Lewis T. Williams , Justin Wong , Hongbing Zhang
IPC: A61K49/00
CPC classification number: A61K49/0008 , A61K2039/505 , C07K16/00 , C07K16/32 , C12N15/85 , C12N2800/30 , C12N2800/80 , C12N2840/20 , G01N33/5088 , G01N2500/10 , G01N2800/52
Abstract: An in vivo method of validating a candidate therapeutic target molecule is provided. An in vivo method of selecting a therapeutic antibody to a specific target molecule is also provided.
Abstract translation: 提供了验证候选治疗靶分子的体内方法。 还提供了选择特定靶分子的治疗性抗体的体内方法。
-
公开(公告)号：US12235264B2
公开(公告)日：2025-02-25
申请号：US17058108
申请日：2019-05-23
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Nallakkan Arvindan , Stephen Mehi , Guanqing Ou
Abstract: An optical imaging system (100) includes a frame (102) designed to provide mechanical coupling between a first stage (104) and a second stage (106), a sample holding region (108) located on the first stage (104), a lens arrangement, and a sensor array. The lens arrangement is disposed between the first stage (104) and the second stage (106) and is designed to receive light from a sample at the sample holding region (108) on the first stage. The lens arrangement has a numerical aperture less than 0.1. The sensor array is coupled to the second stage (106) and is designed to receive light passing through the lens arrangement.
-
公开(公告)号：US12091462B2
公开(公告)日：2024-09-17
申请号：US17258866
申请日：2019-07-10
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Michael Quigley , Hadia Lemar , Akbar Nayeem
CPC classification number: C07K16/2827 , A61P35/00 , A61K2039/507 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20240228578A1
公开(公告)日：2024-07-11
申请号：US17904928
申请日：2021-02-26
Applicant: Five Prime Therapeutics, Inc.
Inventor： Siddhartha MITRA , Maike SCHMIDT , Kathleen M. SULLIVAN
IPC: C07K14/705 , A61K38/00 , A61K39/00 , A61P35/00 , C07K16/28
CPC classification number: C07K14/70532 , A61P35/00 , C07K16/2818 , A61K38/00 , A61K2039/505 , A61K2039/545 , C07K2317/41 , C07K2319/30
Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1), optionally in combination with a PD-1/PD-L1 antagonist, to a subject in need thereof, for example, a cancer patient.
-
公开(公告)号：US20240041979A1
公开(公告)日：2024-02-08
申请号：US17742189
申请日：2022-05-11
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Thomas BRENNAN , David BELLOVIN , Barbara SENNINO , David BUSHA
CPC classification number: A61K38/1774 , C07K16/2818 , C07K16/2827 , A61P35/00 , A61P1/00 , A61K2039/505
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
-
-
-
-
-
-
-
-
Search Results
138
records
(took 0.032 seconds)
